HK1152246A1 - Compositions for treating cancer - Google Patents

Compositions for treating cancer

Info

Publication number
HK1152246A1
HK1152246A1 HK11106406.2A HK11106406A HK1152246A1 HK 1152246 A1 HK1152246 A1 HK 1152246A1 HK 11106406 A HK11106406 A HK 11106406A HK 1152246 A1 HK1152246 A1 HK 1152246A1
Authority
HK
Hong Kong
Prior art keywords
mol
compositions
treating cancer
cholesterol
sphingomyelin
Prior art date
Application number
HK11106406.2A
Other languages
English (en)
Chinese (zh)
Inventor
Clive T R Burge
James H Goldie
Murray S Webb
Patricia M Logan
Andreas H Sarris
Fernando Cabanillas
Lawrence D Mayer
Original Assignee
Talon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talon Therapeutics Inc filed Critical Talon Therapeutics Inc
Publication of HK1152246A1 publication Critical patent/HK1152246A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK11106406.2A 1999-04-01 2011-06-22 Compositions for treating cancer HK1152246A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02

Publications (1)

Publication Number Publication Date
HK1152246A1 true HK1152246A1 (en) 2012-02-24

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106406.2A HK1152246A1 (en) 1999-04-01 2011-06-22 Compositions for treating cancer

Country Status (14)

Country Link
EP (3) EP2266537B1 (pt)
JP (3) JP2002541088A (pt)
AT (1) ATE442839T1 (pt)
AU (1) AU777572B2 (pt)
BR (1) BRPI0009448B8 (pt)
CA (1) CA2366787C (pt)
CY (1) CY1109641T1 (pt)
DE (1) DE60042968D1 (pt)
DK (2) DK2266537T3 (pt)
ES (2) ES2524141T3 (pt)
HK (1) HK1152246A1 (pt)
IL (4) IL145720A0 (pt)
PT (1) PT1169021E (pt)
WO (1) WO2000059473A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
JP2002541088A (ja) * 1999-04-01 2002-12-03 イネックス ファーマシューティカルズ コーポレイション リンパ腫の治療のための組成物および方法
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2002312777B2 (en) * 2001-03-27 2007-07-05 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
ES2521672T3 (es) * 2002-05-17 2014-11-13 Celgene Corporation Formulaciones farmacéuticas para el tratamiento del cáncer
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
BRPI0513007A (pt) * 2004-07-09 2008-04-22 Schering Ag terapia de combinação com anticorpo anti-cd20 marcado radioativamente no tratamento de linfoma de célula b
AU2005272946B2 (en) * 2004-08-10 2012-01-12 Talon Therapeutics, Inc. Compositions and methods for treating leukemia
CA2736564A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
SI2254571T1 (sl) 2008-03-18 2015-10-30 Genentech, Inc. Kombinacije konjugata protitelo proti HER2-zdravilo in kemoterapevtskih sredstev ter postopki uporabe
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy
JP6419710B2 (ja) 2012-11-20 2018-11-07 スペクトラム ファーマシューティカルズ 治療的使用のためのリポソーム封入ビンクリスチンの調製のための改良法
US20140205543A1 (en) * 2013-01-24 2014-07-24 Memorial Sloan-Kettering Cancer Center Method for diagnosing or treating tumors using sphingomyelin containing liposomes
RU2015147696A (ru) 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. Способы лечения злокачественной опухоли
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
JP2002541088A (ja) * 1999-04-01 2002-12-03 イネックス ファーマシューティカルズ コーポレイション リンパ腫の治療のための組成物および方法

Also Published As

Publication number Publication date
AU4060600A (en) 2000-10-23
CY1109641T1 (el) 2014-08-13
PT1169021E (pt) 2009-11-18
AU777572B2 (en) 2004-10-21
IL212389A (en) 2015-07-30
ATE442839T1 (de) 2009-10-15
EP2266537B1 (en) 2014-09-03
JP2012158602A (ja) 2012-08-23
BRPI0009448B1 (pt) 2018-09-11
EP2266537A2 (en) 2010-12-29
EP2266537A3 (en) 2012-02-22
EP1169021A1 (en) 2002-01-09
IL212390A (en) 2014-08-31
BR0009448A (pt) 2002-01-08
DE60042968D1 (de) 2009-10-29
EP1985285A2 (en) 2008-10-29
IL212389A0 (en) 2011-06-30
IL145720A0 (en) 2002-07-25
EP1169021B1 (en) 2009-09-16
DK1169021T3 (da) 2010-01-11
JP5981214B2 (ja) 2016-08-31
WO2000059473A1 (en) 2000-10-12
CA2366787A1 (en) 2000-10-12
ES2524141T3 (es) 2014-12-04
DK2266537T3 (en) 2014-12-15
JP2002541088A (ja) 2002-12-03
EP1985285A3 (en) 2009-08-12
JP2015071631A (ja) 2015-04-16
IL212390A0 (en) 2011-06-30
CA2366787C (en) 2013-03-12
ES2333400T3 (es) 2010-02-22
IL145720A (en) 2011-05-31
BRPI0009448B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HK1152246A1 (en) Compositions for treating cancer
HK1023064A1 (en) Method of inhibiting bacterial or fungal growth using a complexing agent
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
EP0943331A3 (en) Formulations containing oxaliplatin
HK1039328A1 (en) Pyrazolopyrimidinone derivatives for the treatment of impotence
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
AU3268897A (en) Reduction of cardiotoxicity of an antitumor agent using manganese compound
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
PL338181A1 (en) Novel chemical compounds
HK1085675A1 (en) Anticancer compounds
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
GB2358395B (en) Tetrahydrofuran-adducted group 11 ß-diketonate complexes as source reagents for chemical vapor depostion
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
TW230775B (pt)
AU3474495A (en) Functional terpyridine metal complexes, a process for the preparation therof and oligonucleotide conjugates with terpyridine-metal complexes
WO1998003519A3 (en) New bis-platinum complexes with polyamine ligands as antitumor agents
CA2052640A1 (en) Method for destroying cyst of noxious plankton
ES2173464T3 (es) Preparacion de clorinas y bacterioclorinas con contenido en polieter.
ZA987609B (en) Method for the synthesis of taxanes
MX9801130A (es) Tiamacrolidos.
IL114646A0 (en) Method of inhibiting leukotriene biosynthesis
EP1057832A4 (en) SUBSTANCE HAVING A STEROID-LIKE STRUCTURE, METHOD FOR THE PRODUCTION THEREOF, AND ANTI-TUMOR AGENTS CONTAINING THE SAME
UA70975C2 (uk) Похідні 1,4-діарил-2-фтор-1-бутен-3-олу, спосіб їх одержання та способи одержання похідних 1,4-діарил-2-фтор-1,3-бутадієну і 1,4-діарил-2-фтор-2-бутену
MX9802933A (es) Derivados novedosos de amina de 2", 3"-didesoxiglicosidos de epipodofilotoxina, metodo de preparacion de los mismos y uso de los mismos con un farmaco y para tratamientos anticancer.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20200330